FDX1 Antibody

What is FDX1 and what are its primary biological functions?

FDX1 (Ferredoxin-1) is a small iron-sulfur protein that transfers electrons from NADPH through ferredoxin reductase to terminal cytochrome P450 enzymes. It belongs to the adrenodoxin/putidaredoxin family and can only reduce mitochondrial CYP enzymes essential in various biological processes . With a calculated molecular weight of approximately 19 kDa (though often observed at 14 kDa in Western blots), FDX1 is predominantly found in mitochondria .

FDX1 plays critical roles in several biological functions:

• Mitochondrial respiration and energy production

• Biogenesis of mitochondrial cytochrome c oxidase (Complex IV)

• Adrenal steroidogenesis

• Bile acid formation

• Vitamin metabolism

Expression analysis shows highest levels in the adrenal gland, with detection also reported in kidney and testis at the protein level .

What are the common alternative names for FDX1 in the scientific literature?

When searching literature for FDX1-related research, it's important to be aware of its multiple nomenclatures. Common alternative designations include:

• Adrenal ferredoxin

• Adrenodoxin

• Adrenodoxin, mitochondrial

• ADX

• FDX

• Hepatoredoxin

• LOH11CR1D

• Mitochondrial adrenodoxin

The UniProt accession number for human FDX1 is P10109, and its NCBI Gene ID is 2230 .

What types of FDX1 antibodies are commercially available for research?

Current research-grade FDX1 antibodies primarily fall into two categories:

• Polyclonal antibodies:

  • Example: Rabbit polyclonal antibodies (like DF7950) generated against human FDX1

  • Applications: Western blot (WB), immunofluorescence (IF), immunocytochemistry (ICC)

• Monoclonal antibodies:

  • Example: Recombinant monoclonal rabbit IgG (like clone SR1148)

  • Applications: Similar to polyclonal antibodies but may offer higher specificity

Most available antibodies demonstrate primary reactivity with human FDX1, with some showing cross-reactivity with mouse and rat FDX1 . The reactivity prediction for some antibodies extends to other species including pig, zebrafish, bovine, horse, sheep, dog, chicken, and Xenopus, though these predictions are based on sequence alignment and require experimental validation .

What are the optimal conditions for using FDX1 antibodies in Western blot applications?

For optimal Western blot results with FDX1 antibodies, researchers should consider the following parameters:

Recommended dilutions:

• Range varies by manufacturer: 1:500-1:6000

• Examples: 1:1000-1:6000 (Proteintech), 1:500-1:5000 (NovoPro)

Expected molecular weight:

• Calculated: 19 kDa

• Observed: 14-19 kDa (variation may reflect post-translational modifications)

Validated cell lines for positive detection:

• HEK-293 cells

• A549 cells

• HepG2 cells

• PC-3 cells

• HK-2 cells

Sample preparation considerations:

• Standard SDS-PAGE protocols are generally sufficient

• Common loading controls (β-actin, GAPDH) should be included

• Both reducing and non-reducing conditions have been successfully employed

Storage conditions:

• Store antibodies at -20°C

• Glycerol-containing buffers (typically 50%) prevent freeze-thaw damage

• Sodium azide (0.02-0.1%) is commonly used as a preservative

What methods are recommended for immunohistochemical detection of FDX1?

For successful immunohistochemical detection of FDX1, consider these methodological details:

Recommended dilutions:

• Range: 1:20-1:800

• Examples: 1:200-1:800 (Proteintech), 1:20-1:200 (NovoPro)

Antigen retrieval methods:

• Primary recommendation: TE buffer pH 9.0

• Alternative: Citrate buffer pH 6.0

Validated tissue samples showing positive staining:

• Human kidney tissue

• Human liver tissue

• Human intrahepatic cholangiocarcinoma tissue

• Human stomach cancer tissue

Detection systems:

• Both chromogenic (HRP/DAB) and fluorescent secondary antibodies have been validated

• For immunofluorescence applications, similar dilutions (1:50-1:500) are recommended

Expected staining pattern:

• Predominantly mitochondrial localization

• Punctate cytoplasmic distribution consistent with mitochondrial morphology

How should researchers validate the specificity of a new FDX1 antibody?

Comprehensive validation of FDX1 antibodies should include:

Control samples:

• Positive controls: Cell lines with known FDX1 expression (HepG2, A549, HEK-293)

• Negative controls:

  • Isotype-matched irrelevant antibodies

  • Primary antibody omission

  • FDX1 knockout or knockdown cells (if available)

Multi-method validation:

• Western blot: Should show a single band of expected molecular weight (14-19 kDa)

• Immunofluorescence: Should demonstrate mitochondrial localization pattern

• Immunohistochemistry: Should show expected tissue distribution (high in adrenal, kidney, testis)

Specificity tests:

• Peptide competition assay: Pre-incubation with immunizing peptide should abolish signal

• siRNA knockdown: Reduction in signal intensity proportional to knockdown efficiency

• Comparison with published data: Staining patterns should match established literature

Cross-validation approaches:

• Use multiple antibodies targeting different epitopes of FDX1

• Compare results from different antibody suppliers

• Correlate protein detection with mRNA expression data

What is the evidence supporting anti-FDX1 autoantibody as a biomarker for non-small cell lung cancer?

Recent research has identified anti-FDX1 autoantibody as a promising novel biomarker for non-small cell lung cancer (NSCLC) detection. The key findings include:

Study design and cohort:

• Total samples: 1,155 plasma samples divided into verification and validation groups

• Participants: 414 NSCLC patients, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC)

Detection methodology:

• Primary method: Enzyme-linked immunosorbent assay (ELISA)

• Confirmation methods: Western blotting and immunofluorescence analyses

Key findings:

• Significantly higher plasma anti-FDX1 autoantibody levels in NSCLC patients compared to BPN patients and normal controls

• Consistent elevation observed in both verification and validation cohorts

• Diagnostic performance: Anti-FDX1 autoantibody distinguished NSCLC from normal controls with AUC of 0.806 (95% CI: 0.772-0.839)

• Differentiation performance: Distinguished NSCLC from BPN with AUC of 0.627 (95% CI: 0.584-0.670)

Clinical implications:

• Potential for early detection of NSCLC before biopsy becomes necessary

• Possible incorporation into multi-biomarker panels to improve sensitivity and specificity

• May facilitate screening in high-risk populations

How is FDX1 expression associated with glioma progression and prognosis?

Research examining FDX1's role in glioma has revealed important associations with disease progression and patient outcomes:

Expression analysis:

• High FDX1 expression correlates with poor prognosis in glioma patients as demonstrated through Kaplan-Meier analysis

• Data sources: Cancer Genome Atlas and Chinese Glioma Genome Atlas databases

Functional associations:

• Function and pathway enrichment analysis revealed FDX1 predominantly demonstrates immunomodulatory function

• High-FDX1 expression group had significantly higher stromal and immune scores (p<0.001)

Immune microenvironment impact:

• Evaluation of immunotherapy response showed that TIDE and dysfunction scores were higher in the low-FDX1 group

• Suggests potential implications for immunotherapy strategies

Experimental validation:

• In vitro experiments confirmed FDX1's impact on malignant phenotypes of glioma cells

• Provides mechanistic support for the clinical associations

These findings suggest that FDX1 expression analysis could serve as a prognostic indicator and potentially guide treatment decisions in glioma management.

What methodological approaches are used to study FDX1's role in cancer biomarker research?

Investigation of FDX1 as a cancer biomarker employs several complementary methodological approaches:

Autoantibody detection methods:

• ELISA: Primary screening method for large-scale plasma sample analysis

• Western blotting: Confirmation of autoantibody specificity

• Immunofluorescence: Visualization of antigen recognition patterns

Expression analysis techniques:

• RNA sequencing: Assessment of FDX1 mRNA expression levels

• Immunohistochemistry: Protein expression in tumor tissues

• Western blotting: Protein quantification in cell lines and tissue lysates

Functional validation approaches:

• Gene knockdown/knockout: CRISPR-Cas9 or siRNA to assess functional consequences

• Overexpression studies: Examine effects of increased FDX1 levels

• Cell proliferation, migration, and invasion assays: Evaluate impact on cancer hallmarks

Clinical correlation methods:

• Survival analysis: Kaplan-Meier curves and Cox regression

• Receiver operating characteristic (ROC) analysis: Assess diagnostic performance

• Multivariate analysis: Control for confounding variables

What is the specific role of FDX1 in mitochondrial cytochrome c oxidase biogenesis?

FDX1 plays a critical and specific role in the biogenesis of mitochondrial cytochrome c oxidase (CcO, Complex IV), as evidenced by multiple experimental approaches:

Key experimental evidence:

• FDX1 knockout (Fdx1-/-) cells showed severely reduced cell proliferation when forced to generate ATP through oxidative phosphorylation

• Oxygen consumption rate (OCR) measurements revealed pronounced reduction in both basal and maximal respiration in Fdx1-/- cells

• SDS-PAGE immunoblot analysis demonstrated specific reduction in Complex IV subunits COX1 and COX4, while other OXPHOS complexes remained unaffected

Mechanistic insights:

• Blue native PAGE analysis revealed that FDX1 loss specifically reduces the abundance of CIV-containing complexes and supercomplexes

• The defect appears linked to the conversion of heme o to heme a, which is required for CcO assembly

• Overexpression of COX15 in Fdx1-/- cells partially rescued COX1 levels, implicating FDX1 in the heme o to heme a conversion pathway

Specificity of function:

• Complementation experiments showed that FDX1, but not the related protein FDX2, can rescue COX1 and COX4 levels in Fdx1-/- cells

• This rescue translated to increased CcO activity, confirming the functional significance

These findings establish FDX1 as an essential component in the biogenesis pathway of cytochrome c oxidase, with implications for understanding mitochondrial diseases and potential therapeutic interventions.

How does FDX1 influence Fe-S cluster function despite not being essential for Fe-S cluster assembly?

The relationship between FDX1 and Fe-S cluster biology presents an intriguing paradox:

Observations from knockout studies:

• FDX1 knockout did not alter abundance of Fe-S-containing subunits of OXPHOS complexes (SDHB, UQCRSF1)

• Levels of other Fe-S-containing proteins like mitochondrial aconitase (ACO2) and lipoyl synthase (LIAS) remained unchanged

Functional impact despite normal protein levels:

• Despite normal protein abundance, mitochondrial aconitase enzyme activity was decreased by approximately 60% in Fdx1-/- cells

• This suggests FDX1 impacts the functionality rather than the assembly of Fe-S proteins

Potential mechanisms explaining this discrepancy:

• Redox state modulation: FDX1 may help maintain the proper redox environment for optimal Fe-S cluster function

• Indirect regulatory effects: FDX1 could influence post-translational modifications affecting Fe-S enzyme activity

• Electron transfer functions: As an electron transfer protein, FDX1 might directly participate in redox reactions necessary for Fe-S enzyme catalysis

• Mitochondrial homeostasis: General perturbations in mitochondrial function upon FDX1 loss may secondarily impact Fe-S enzyme activity

Methodological approaches to investigate this phenomenon:

• Enzymatic activity assays for multiple Fe-S proteins

• Redox state analysis of Fe-S clusters using EPR spectroscopy

• Assessment of Fe-S cluster integrity through iron incorporation assays

• Evaluation of mitochondrial redox potential in FDX1-deficient cells

What experimental approaches are most effective for studying FDX1's electron transfer functions?

Investigating FDX1's electron transfer capabilities requires specialized techniques:

Biochemical and biophysical approaches:

• Electron paramagnetic resonance (EPR) spectroscopy: Directly observes the redox state of FDX1's Fe-S cluster

• Protein-protein interaction studies: Co-immunoprecipitation, crosslinking mass spectrometry, or surface plasmon resonance to identify and characterize interactions with electron donor/acceptor proteins

• Reconstituted electron transfer systems: In vitro reconstitution of electron transfer chains with purified components

• Steady-state kinetics: Measurement of electron transfer rates under varying substrate concentrations

Cellular and genetic approaches:

• Site-directed mutagenesis: Modification of key residues in the electron transfer pathway

• Domain swapping experiments: Exchange domains between FDX1 and related proteins (e.g., FDX2) to identify specificity determinants

• Inducible expression systems: Control FDX1 levels to establish dose-dependent effects

• Live-cell imaging: Use of redox-sensitive fluorescent probes to visualize electron transfer dynamics

Combined methodologies:

• Structure-function analysis: Correlate structural information with functional data

• Systems biology approaches: Metabolic flux analysis to determine the impact of FDX1 on electron flow through various pathways

• Comparative studies: Examine FDX1 function across different cell types and organisms

These approaches can provide complementary insights into FDX1's role in electron transfer processes and its specific contributions to mitochondrial function.

What are common challenges when using FDX1 antibodies and their solutions?

Researchers may encounter several challenges when working with FDX1 antibodies:

How can researchers optimize detection of mitochondrial FDX1 in immunofluorescence studies?

Optimizing immunofluorescence detection of FDX1 requires attention to its mitochondrial localization:

Sample preparation considerations:

• Fixation method: 10% formaldehyde fixation has been validated for HepG2 cells

• Permeabilization: Balance between sufficient permeabilization for antibody access and preservation of mitochondrial structure

• Mitochondrial morphology preservation: Consider gentle fixation protocols that maintain native mitochondrial networks

Staining protocol optimization:

• Antibody dilution: Start with 1:50-1:200 dilution and optimize based on signal-to-noise ratio

• Co-staining: Include mitochondrial markers (MitoTracker, TOMM20, or COX4) for colocalization analysis

• Secondary antibody selection: Anti-rabbit IgG conjugated to bright fluorophores (Alexa Fluor 488 has been validated)

Imaging considerations:

• Confocal microscopy: Necessary for precise mitochondrial localization

• Z-stack acquisition: Capture the three-dimensional distribution of mitochondria

• Deconvolution: Consider computational deconvolution to improve resolution

• Quantitative analysis: Use colocalization coefficients (Pearson's, Mander's) to quantify mitochondrial localization

Validation approaches:

• Mitochondrial fractionation: Confirm FDX1 enrichment in mitochondrial fraction by Western blot

• siRNA knockdown: Demonstrate reduction in mitochondrial signal upon FDX1 depletion

• Super-resolution microscopy: For detailed analysis of submitochondrial localization

What considerations are important when designing experiments to study FDX1 in disease contexts?

When investigating FDX1 in disease research, several experimental design considerations are essential:

Sample selection and controls:

• Tissue heterogeneity: Account for variability in FDX1 expression across tissues (highest in adrenal, detected in kidney and testis)

• Appropriate controls: Include both healthy tissue and disease-relevant controls (e.g., benign nodules for cancer studies)

• Sample size calculation: Ensure adequate statistical power based on expected effect sizes

Methodological approaches:

• Multi-omics integration: Combine protein expression data with transcriptomics and functional assays

• In vitro models: Validate findings in relevant cell lines (A549 for lung cancer, glioma cell lines for brain tumors)

• In vivo models: Consider transgenic models with altered FDX1 expression

Disease-specific considerations:

• Cancer research: Assess both tumor cells and the tumor microenvironment due to FDX1's immunomodulatory functions

• Autoantibody studies: Include multiple validation techniques (ELISA, Western blot, IF) as demonstrated in NSCLC research

• Prognostic biomarker evaluation: Correlate with established clinical parameters and long-term outcomes

Technical validations:

• Antibody specificity: Particularly important in autoantibody studies

• Reference gene selection: Choose appropriate housekeeping genes for normalization

• Statistical analysis: Apply appropriate tests for the specific experimental design and data distribution

By addressing these considerations, researchers can design robust experiments to investigate FDX1's role in disease pathophysiology and its potential as a biomarker or therapeutic target.

What are promising future directions for FDX1 research in cancer biology?

Based on current findings, several promising research directions emerge for FDX1 in cancer biology:

Expanding biomarker applications:

• Evaluate anti-FDX1 autoantibodies across additional cancer types beyond NSCLC

• Develop multi-biomarker panels incorporating FDX1 to improve sensitivity and specificity

• Investigate longitudinal changes in FDX1 expression or autoantibody levels during cancer progression and treatment

Mechanisms in cancer metabolism:

• Explore how FDX1's role in mitochondrial function impacts cancer cell metabolism

• Investigate connections between FDX1 and the Warburg effect or metabolic plasticity

• Examine potential links between FDX1 and tumor hypoxia responses

Therapeutic targeting opportunities:

• Assess whether FDX1 inhibition selectively affects cancer cells with altered metabolism

• Explore synthetic lethality approaches targeting FDX1-dependent pathways

• Investigate immunotherapeutic approaches based on FDX1's immunomodulatory functions

Integration with emerging cancer biology concepts:

• Explore FDX1's relationship with ferroptosis and cuproptosis pathways

• Investigate FDX1's role in cancer stem cell maintenance

• Examine connections between FDX1 and tumor microenvironment remodeling

How might advances in technology impact future FDX1 antibody applications?

Technological advances will likely transform FDX1 antibody applications in several ways:

Next-generation antibody technologies:

• Single-cell proteomics for FDX1 detection with spatial resolution

• Development of recombinant antibody fragments (Fab, scFv) with improved tissue penetration

• Bispecific antibodies targeting FDX1 and complementary biomarkers

• Engineered antibodies optimized for specific applications (super-resolution microscopy, in vivo imaging)

Advanced imaging applications:

• Super-resolution microscopy for submitochondrial localization of FDX1

• Multiplexed imaging to simultaneously detect FDX1 and interaction partners

• Intravital microscopy to study FDX1 dynamics in living organisms

• Correlative light and electron microscopy for ultrastructural context

Diagnostic platform innovations:

• Microfluidic-based detection of anti-FDX1 autoantibodies

• Point-of-care testing systems for rapid assessment

• Digital pathology and AI-assisted quantification of FDX1 immunostaining

• Liquid biopsy applications leveraging anti-FDX1 autoantibodies

Therapeutic applications:

• Antibody-drug conjugates targeting FDX1 in cancer cells

• CAR-T cell therapies directed against FDX1-expressing tumors

• Nanoparticle-conjugated antibodies for targeted drug delivery

• Intrabodies for modulating FDX1 function in specific cellular compartments

What interdisciplinary approaches might advance our understanding of FDX1 biology?

Progress in FDX1 research will benefit from integrative approaches spanning multiple disciplines:

Computational and systems biology:

• Network analysis to place FDX1 in broader cellular pathways

• Machine learning approaches to identify patterns in FDX1 expression across diseases

• Molecular dynamics simulations of FDX1's electron transfer mechanisms

• Multi-omics data integration to understand FDX1 regulation

Structural biology and biophysics:

• Cryo-EM structures of FDX1 in complex with interaction partners

• Single-molecule biophysics to study electron transfer kinetics

• Hydrogen-deuterium exchange mass spectrometry for conformational dynamics

• Time-resolved spectroscopy for measuring electron transfer rates

Chemical biology:

• Development of selective FDX1 inhibitors or activators

• Activity-based protein profiling to identify FDX1-dependent processes

• Engineered FDX1 variants with modified electron transfer properties

• Photocaged FDX1 substrates for spatiotemporal control

Translational research:

• Biomarker validation in large, diverse patient cohorts

• Development of standardized clinical assays for FDX1 detection

• Integration with existing diagnostic workflows

• Assessment of FDX1-targeted therapies in preclinical models

By embracing these interdisciplinary approaches, researchers can develop a more comprehensive understanding of FDX1 biology and accelerate its translation into clinical applications.